BridgeBio Pharma Outlines Clinical Wins, Commercial Momentum, and Tafamidis IP Trial

CEO Neil Kumar discusses the company's recent progress, upcoming regulatory plans, and market opportunities during a healthcare conference.

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

BridgeBio Pharma CEO Neil Kumar provided an update on the company's clinical pipeline, commercial performance, and upcoming intellectual property trial related to tafamidis during a fireside chat at a healthcare conference. Kumar highlighted positive Phase 3 results for several of BridgeBio's programs, including in ADH1, LGMD2I, and achondroplasia. He also addressed investor concerns around the pending tafamidis IP trial, expressing confidence in BridgeBio's position. Additionally, Kumar discussed the commercial launch of Atrubie, growth drivers, and the overall market opportunity for ATTR cardiomyopathy. The CEO also provided updates on upcoming product launches, pipeline priorities, and a program in erythropoietic protoporphyria from BridgeBio's affiliate GondolaBio.

Why it matters

BridgeBio's update provides insights into the company's clinical and commercial progress, as well as its strategy to navigate the upcoming tafamidis IP trial. The outcomes of these developments could significantly impact the company's future growth and competitive positioning in the rare disease and genetic disorder treatment landscape.

The details

During the fireside chat, Kumar outlined BridgeBio's recent clinical successes, including positive Phase 3 results for its programs in ADH1, LGMD2I, and achondroplasia. He also addressed investor concerns around the upcoming tafamidis IP trial, expressing confidence in BridgeBio's position and arguing that the company has "very, very strong arguments" on both infringement and validity. On the commercial front, Kumar characterized the launch performance of Atrubie (acoramidis) as improving over time, citing better patient identification, expansion beyond academic medical centers, and additional clinical data. He also discussed the potential for the ATTR cardiomyopathy market to become a $20 billion opportunity. Looking ahead, Kumar said BridgeBio expects upcoming product launches to be "materially cheaper" than the Atrubie launch, as the company has already built out its commercial infrastructure. The CEO also provided updates on pipeline priorities, including programs in erythropoietic protoporphyria (EPP) from BridgeBio's affiliate GondolaBio.

  • The tafamidis IP trial is scheduled for late April 2026.
  • BridgeBio expects to launch both its ADH1 and LGMD2I programs in the first half of 2027.
  • Data in hypochondroplasia are expected later this year, with Phase 3 potentially starting next year.

The players

Neil Kumar

CEO of BridgeBio Pharma, a clinical-stage biopharmaceutical company dedicated to discovering, developing, and delivering transformative medicines for patients with genetic diseases and cancers.

Pfizer

A global pharmaceutical company that owns the rights to tafamidis, a drug that is the subject of an upcoming intellectual property trial with BridgeBio.

GondolaBio

An affiliate of BridgeBio Pharma that is developing a program in erythropoietic protoporphyria (EPP).

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, Grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.